pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

PD-1 inhibitors therapy

Medication Total (n=215) P-value

Nivolumab (n=115) Pembrolizumab (n=100)
Administration reason, n(%) <0.001*
1st therapy 8 (7.0) 21 (21.0) 29 (13.5)
d/t AE of prior chemotherapy 2 (1.7) 2 (2.0) 4 (1.9)
d/t PD of prior chemotherapy 105 (91.3) 71 (71.0) 176 (81.9)
change to immunotherapy 0 (0.0) 6 (6.0) 6 (2.8)
d/t poor condition
Number of PD-1 inhibitors cycle, median(range) 3 (1-37) 2 (1-25) 3 (1-37) 0.149
Dosage modification, n(%) 0.420
Increase 0 (0.0) 0 (0.0) 0 (0.0)
Decrease 2 (1.7) 4 (4.0) 6 (2.8)
Maintain 113 (98.3) 96 (96.0) 209 (97.2)
Dosing progress, n(%) 0.299
Continue treatment 6 (5.2) 7 (7.0) 13 (6.0)
Discontinue d/t AE 0 (0.0) 2 (2.0) 2 (0.9)
Discontinue d/t PD 68 (59.1) 57 (57.0) 125 (58.1)
Discontinue d/t cost 4 (3.5) 1 (1.0) 5 (2.3)
Supportive care 9 (7.8) 5 (5.0) 14 (6.5)
Death d/t disease 12 (10.4) 12 (12.0) 24 (11.2)
Transfer to others 7 (6.1) 2 (2.0) 9 (4.2)
Follow-up loss 9 (7.8) 14 (14.0) 23 (10.7)

AE, adverse events; PD, progressive disease; d/t, due to

*indicates P<0.05

Korean J Clin Pharm 2021;31:188-97 https://doi.org/10.24304/kjcp.2021.31.3.188
© 2021 Korean J Clin Pharm